OncoMatch/Clinical Trials/NCT07330050

WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC

Is NCT07330050 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Whole Agonist-Stimulated T (WAST) cells and Docetaxel for nsclc (non-small cell lung cancer).

Phase 2RecruitingTianjin Medical University Cancer Institute and HospitalNCT07330050Data as of May 2026

Treatment: Whole Agonist-Stimulated T (WAST) cells · Docetaxel — This prospective Phase II study aims to evaluate the preliminary efficacy and safety of WAST cells combined with docetaxel as second-line therapy in patients with advanced NSCLC resistant to PD-1 inhibitors.

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Small Cell Lung Carcinoma

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Min 1 prior line

Must have received: anti-pd-1 therapy — first-line

Cannot have received: adoptive cell therapy

Lab requirements

Blood counts

ANC >1.5×10⁹/L; ALC ≥0.3×10⁹/L; Platelets ≥100×10⁹/L; Hemoglobin ≥100g/L

Kidney function

Serum creatinine ≤1.5x ULN, or creatinine clearance rate ≥60 mL/min

Liver function

AST ≤2.5x ULN (≤5 ULN if due to tumor infiltration); ALT ≤2.5x ULN (≤5 ULN if due to tumor infiltration); Total serum bilirubin ≤1.5x ULN (≤3 ULN if due to tumor infiltration)

Cardiac function

LVEF ≤50% (by ECHO); NYHA class III or IV congestive heart failure; Uncontrolled hypertension (systolic BP ≥140 mmHg and/or diastolic BP ≥90 mmHg) or pulmonary hypertension despite standard treatment; Myocardial infarction or cardiac surgery within 12 months prior to cell infusion; Clinically significant valvular heart disease

Adequate organ function at screening, meeting the following criteria: AST ≤2.5x ULN (≤5 ULN if due to tumor infiltration); ALT ≤2.5x ULN (≤5 ULN if due to tumor infiltration); Total serum bilirubin ≤1.5x ULN (≤3 ULN if due to tumor infiltration); Serum creatinine ≤1.5x ULN, or creatinine clearance rate ≥60 mL/min; Minimum lung reserve level, defined as ≤Grade 1 dyspnea and oxygen saturation >91% without supplemental oxygen; INR ≤1.5x ULN, and APTT ≤1.5x ULN

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify